These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2530897)

  • 1. Newborn's fibrinolytic mechanism: components and plasmin generation.
    Corrigan JJ; Sleeth JJ; Jeter M; Lox CD
    Am J Hematol; 1989 Dec; 32(4):273-8. PubMed ID: 2530897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during shock.
    Siebeck M; Spannagl M; Hoffmann H; Schramm W; Fritz H
    Blood Coagul Fibrinolysis; 1991 Jun; 2(3):459-64. PubMed ID: 1834237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
    Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns.
    Corrigan JJ; Jeter MA
    Pediatrics; 1992 Jan; 89(1):43-6. PubMed ID: 1728019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen and plasmin activity in patients with coronary artery disease.
    Drinane MC; Sherman JA; Hall AE; Simons M; Mulligan-Kehoe MJ
    J Thromb Haemost; 2006 Jun; 4(6):1288-95. PubMed ID: 16706973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Fibrinolytic System in Health and Disease.
    Kwaan HC
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
    Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
    Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myosin as cofactor and substrate in fibrinolysis.
    Machovich R; Ajtai K; Kolev K; Owen WG
    FEBS Lett; 1997 Apr; 407(1):93-6. PubMed ID: 9141488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
    Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.
    Levin RI; Harpel PC; Harpel JG; Recht PA
    Blood; 1989 Oct; 74(5):1635-43. PubMed ID: 2529003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults.
    Ries M; Klinge J; Rauch R; Trusen B; Zenker M; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):346-51. PubMed ID: 8888740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female.
    Urano T; Sumiyoshi K; Nakamura M; Mori T; Takada Y; Takada A
    Thromb Res; 1990 Oct; 60(2):133-9. PubMed ID: 2126399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
    Ries M; Klinge J; Rauch R; Keuper H; Harms D
    Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
    Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Díaz-Gomez F; Pacheco-Pantoja E; Drenkard C; Alarcón-Segovia D
    Am J Hematol; 1991 May; 37(1):9-13. PubMed ID: 1902623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.